Dear all, I don’t know if this has been discussed in this forum, but there are awesome good news in which I think the community must be focussed now.
THE 4TH OCTOBER 2024, EUROPEAN MEDICINES AGENCY (EMA) HAS REOPENED THE SAFETY ANALYSIS OF FINASTERIDE/DUTASTERIDE DRUGS DUE TO SUCIDAL IDEATION AND BEHAVIORS SIDE EFECTS.
THIS COULD LEAD, IN THE BEST SCENARIO FOR US, IN THE WITHDRAVAL FROM THE MARKET OF THIS DRUGS IN AROUND 30 COUNTRIES OF EUROPAN UNION. THIS WOULD AUTOMATICALLY RECOGNIZE OUR CONDITION AND THE DANGER THIS DRUGS ARE.
THIS IS A HUGE OPPORTUNITY FOR ALL OF US, THE VICTIMS.
WE CANNOT LOOSE THIS OPORTUNITY!!
WHAT WE ALL MUST DO NOW:
1- REPORT THE SIDES (MAINLY THE PSIQUIATRICAL AND SUCIDAL THOUGTHS) TO THE PHARMACOVIGILANGE AGENCY OF YOUR EUROPEAN COUNTRY.
2- FILL IN THE AVFIN (French Victims Association) SURVEY INCLUDING THE REPORTING NUMBER OF YOUR CASE AT THE END OF THE SURVEY. AVFIN has made possible what seemed imposible, putting this subjet on the table of European Medicines Agency.
PLEASE, EVERYBODY MUST DO THIS.
AFTER INVESTIGATION OF CASES REPORTED, EMA WILL DECIDE IF FINASTERIDE MUST BE RETIRED FROM THE EUROPEAN MARKET TAKING INTO ACCOUNT THE RISK/BENNEFIT BALANCE OF THE DRUG.
IT CAN BE THE BIGGEST VICTORY OF VICTIMS IN THE HISTORY OF PFS, AND IT IS IN OUR HANDS TO GET IT.
FIND BELOW THE LINKS TO THE PROCESS OPENED BY EMA AND TO THE AVFIN SURVEY.
EUROPEAN MEDICINES AGENCY (EMA) OFFICIAL COMMUNICATION:
“During the review, PRAC will assess all available data linking finasteride and dutasteride to suicidal ideation and behaviours. It will also evaluate the impact of suicidal ideation and behaviours on the benefit-risk balance of these medicines, taking into consideration the conditions they are used to treat.”
“EMA will now review all available data on suicidal ideation and behaviours with finasteride and dutasteride and issue a recommendation on whether the marketing authorisations for these medicines should be maintained, varied, suspended or withdrawn across the EU.”
AVFIN ASSOCIATION SURVEY: